Summary
This systematic review and meta-analysis asked whether pulmonary rehabilitation affects adults with long COVID-19. The authors searched randomized controlled trials published before April 2024 and included 37 studies with 3363 patients. Pulmonary rehabilitation was compared with controls receiving usual care, no treatment, educational material, a sham device, or unsupervised rehabilitation. Programs were grouped by duration (≤4, 4–8, and >8 weeks) and by exercise type (breathing, multicomponent, or both). Outcomes included 6MWT, lung function (FEV1, FVC, MIP, MEP), HRQoL, fatigue, 30STST, handgrip, dyspnea, depression, anxiety, perceived effort, and adverse events. The review reports improvement in 6MWT with a mean difference of 77.95 m (95% CI 50.91–104.99 m), and improvements in 30STST, handgrip, lung function, HRQoL, fatigue, dyspnea, and anxiety, but no effect on depression was detected. Subgroups: ≤4 weeks improved 6MWT but not FEV1, FVC, HRQoL, or fatigue; 4–8 weeks improved 6MWT, FEV1, FVC, HRQoL, and fatigue; >8 weeks improved HRQoL and fatigue but no additional 6MWT, FEV1, or FVC. Breathing exercises improved 6MWT, lung function, and HRQoL without fatigue effect; multicomponent exercises improved 6MWT and fatigue without lung function or HRQoL effects; combined exercises improved 6MWT, FEV1, FVC, HRQoL, and fatigue. Adverse events were reported in 16 RCTs: nine found none in either group; two reported events in both groups; one reported minor oxygen desaturations in the intervention group; three reported control-group events; one reported reinfection without specifying group. GRADE certainty was low to moderate, and the authors state bias may have overestimated outcomes.